Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Calliditas Therapeutics AB - A - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CALT
Nasdaq
2834
https://www.calliditas.se/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Calliditas Therapeutics AB - A
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Mar 12th, 2024 1:28 am
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
- Mar 6th, 2024 7:38 am
Calliditas Therapeutics to Attend Investor Conferences in March
- Mar 1st, 2024 12:43 pm
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript
- Feb 22nd, 2024 4:15 pm
Calliditas Year-end report, January - December 2023
- Feb 21st, 2024 6:45 am
Invitation to the presentation of Calliditas´ Year-end report January - December 2023
- Feb 14th, 2024 6:11 am
Calliditas provides patent update
- Feb 13th, 2024 4:28 pm
Calliditas Therapeutics provides business update ahead of JP Morgan conference
- Jan 8th, 2024 7:33 am
Calliditas Therapeutics appoints Maria Törnsén as President North America
- Jan 7th, 2024 4:21 pm
Calliditas to present at JP Morgan Healthcare Conference
- Jan 7th, 2024 4:07 pm
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
- Dec 27th, 2023 5:22 pm
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
- Dec 20th, 2023 9:34 pm
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
- Dec 11th, 2023 2:39 pm
Calliditas announces additions to the management team
- Dec 1st, 2023 8:26 am
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
- Nov 30th, 2023 7:55 am
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
- Nov 24th, 2023 8:13 am
Calliditas to present at upcoming investor conferences
- Nov 7th, 2023 3:31 pm
Calliditas Interim Report January - September 2023
- Nov 7th, 2023 6:32 am
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
- Nov 7th, 2023 1:03 am
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
- Oct 27th, 2023 7:29 am
Scroll